Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Phase II Clinical Study to Evaluate the Safety and Efficacy of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B

NCT04568265 is registered in ClinicalTrials.gov with Ascentage Pharma Group Inc. as lead sponsor.

NCT NCT04568265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04568265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Phase II Clinical Study to Evaluate the Safety and Efficacy of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B
Lead sponsor
Ascentage Pharma Group Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
June 3, 2020
Completion date
October 31, 2025
Enrollment
122 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hep b, hbv, hepatitis b